Prostatic Neoplasms

"Prostatic Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Tumors or cancer of the PROSTATE.

Descriptor ID	D011471
MeSH Number(s)	C04.588.945.440.770 C12.294.260.750 C12.294.565.625 C12.758.409.750
Concept/Terms	Prostatic Neoplasms Prostatic Neoplasms Prostate Neoplasms Neoplasms, Prostate Neoplasm, Prostate Prostate Neoplasm Neoplasms, Prostatic Neoplasm, Prostatic Prostatic Neoplasm Prostate Cancer Prostate Cancer Cancer, Prostate Cancers, Prostate Prostate Cancers Cancer of the Prostate Prostatic Cancer Cancer, Prostatic Cancers, Prostatic Prostatic Cancers Cancer of Prostate

Below are MeSH descriptors whose meaning is more general than "Prostatic Neoplasms".

Diseases [C]
Neoplasms [C04]
Neoplasms by Site [C04.588]
Urogenital Neoplasms [C04.588.945]
Genital Neoplasms, Male [C04.588.945.440]
Prostatic Neoplasms [C04.588.945.440.770]
Male Urogenital Diseases [C12]
Genital Diseases, Male [C12.294]
Genital Neoplasms, Male [C12.294.260]
Prostatic Neoplasms [C12.294.260.750]
Prostatic Diseases [C12.294.565]
Prostatic Neoplasms [C12.294.565.625]
Urogenital Neoplasms [C12.758]
Genital Neoplasms, Male [C12.758.409]
Prostatic Neoplasms [C12.758.409.750]

Below are MeSH descriptors whose meaning is related to "Prostatic Neoplasms".

Below are MeSH descriptors whose meaning is more specific than "Prostatic Neoplasms".

Prostatic Neoplasms
Prostatic Neoplasms, Castration-Resistant

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Prostatic Neoplasms" by people in this website by year, and whether "Prostatic Neoplasms" was a major or minor topic of these publications.

Bar chart showing 245 publications over 27 distinct years, with a maximum of 19 publications in 2004

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	1	0	1
1996	3	0	3
1998	4	0	4
2000	4	0	4
2001	1	0	1
2002	9	3	12
2003	8	3	11
2004	15	4	19
2005	14	0	14
2006	7	2	9
2007	12	1	13
2008	13	1	14
2009	8	3	11
2010	10	1	11
2011	13	1	14
2012	11	0	11
2013	13	1	14
2014	14	3	17
2015	11	5	16
2016	9	0	9
2017	6	1	7
2018	9	0	9
2019	4	2	6
2020	9	0	9
2021	3	0	3
2022	2	0	2
2023	1	0	1

Below are the most recent publications written about "Prostatic Neoplasms" by people in Profiles.

Wang M, Wisniewski CA, Xiong C, Chhoy P, Goel HL, Kumar A, Zhu LJ, Li R, St Louis PA, Ferreira LM, Pakula H, Xu Z, Loda M, Jiang Z, Brehm MA, Mercurio AM. Therapeutic blocking of VEGF binding to neuropilin-2 diminishes PD-L1 expression to activate antitumor immunity in prostate cancer. Sci Transl Med. 2023 05 03; 15(694):eade5855.

View in: PubMed
Epstein MM, Sundaresan D, Fair M, Fouayzi H, Warner ET, Garber LD, Gurwitz JH, Field TS. Trends in breast and prostate cancer screening and diagnostic procedures during the COVID-19 pandemic in central Massachusetts. Cancer Causes Control. 2022 Oct; 33(10):1313-1323.

View in: PubMed
Walz J. Re: Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients with Localized Prostate Cancer: Results from the FLAME Randomized Phase III Trial. Eur Urol. 2022 05; 81(5):544-545.

View in: PubMed
Rizzo A, Santoni M, Mollica V, Fiorentino M, Brandi G, Massari F. Microbiota and prostate cancer. Semin Cancer Biol. 2022 Nov; 86(Pt 3):1058-1065.

View in: PubMed
Baltz JO, Vatanchi M, Jellinek NJ. Retronychia Triggered by Docetaxel. Dermatol Surg. 2021 06 01; 47(6):884-885.

View in: PubMed
Yang L, Lee JA, Heer E, Pernar C, Colditz GA, Pakpahan R, Imm KR, Kim EH, Grubb RL, Wolin KY, Kibel AS, Sutcliffe S. One-year urinary and sexual outcome trajectories among prostate cancer patients treated by radical prostatectomy: a prospective study. BMC Urol. 2021 May 17; 21(1):81.

View in: PubMed
Rosellini M, Santoni M, Mollica V, Rizzo A, Cimadamore A, Scarpelli M, Storti N, Battelli N, Montironi R, Massari F. Treating Prostate Cancer by Antibody-Drug Conjugates. Int J Mol Sci. 2021 Feb 04; 22(4).

View in: PubMed
Berry DL, Hong F, Blonquist TM, Halpenny B, Xiong N, Filson CP, Master VA, Sanda MG, Chang P, Chien GW, Jones RA, Krupski TL, Wolpin S, Wilson L, Hayes JH, Trinh QD, Sokoloff M. Decision regret, adverse outcomes, and treatment choice in men with localized prostate cancer: Results from a multi-site randomized trial. Urol Oncol. 2021 08; 39(8):493.e9-493.e15.

View in: PubMed
Aurilio G, Cimadamore A, Mazzucchelli R, Lopez-Beltran A, Verri E, Scarpelli M, Massari F, Cheng L, Santoni M, Montironi R. Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications. Cells. 2020 12 10; 9(12).

View in: PubMed
Souza AG, Bastos VAF, Fujimura PT, Ferreira ICC, Leal LF, da Silva LS, Laus AC, Reis RM, Martins MM, Santos PS, Corr?a NCR, Marangoni K, Thom? CH, Colli LM, Goulart LR, Goulart VA. Cell-free DNA promotes malignant transformation in non-tumor cells. Sci Rep. 2020 12 10; 10(1):21674.

View in: PubMed

People

Explore

Similar Concepts

Top Journals